Your Insurer Would Like to Be Your Lender, Too

The catalyst

The Trump administration wants the company that wrote your insurance policy to also write you a loan. Under the approach being floated, people who develop a costly disease or need unexpected emergency care could turn to their health insurer for loans to cover their share of the bill, debt that would have to be repaid, presumably with interest. Officials pitch it as help for people who chose a plan with a low monthly premium and high out-of-pocket costs and then encounter a devastating bill.

Those shares are no longer modest. For 2026, the annual deductible on an ACA catastrophic plan is $10,600 for an individual or $21,200 for a family. A rule finalized last month allows people to enroll in catastrophic plans with terms of up to 10 years, and from 2028 those plans' out-of-pocket maximums will be set at 130 percent of the standard cap. The enhanced ACA subsidies expired at the end of last year, and KFF estimated the lapse would cause premiums to more than double for the average recipient. Stanford economist Neale Mahoney called the lending idea “hugely out of touch with where people are.”

The deep issue

The scandal is not that someone said “get a loan.” It is who the lender would be. Insurance exists to pool risk; a loan individualizes it. Under this proposal, a single balance sheet holds three roles at once: the firm that sets your deductible, the firm that adjudicates your claim, and the firm that profits from financing the gap between them. Each role corrupts the others. An insurer-creditor earns twice on the cost-sharing it designed, and a loan book gives the claims department a window into the patient's finances that no adjudicator should have. There is also a neat inversion of the industry's favorite concept: deductibles were always justified as a check on patient moral hazard. An insurer holding loans whose returns depend on cost-sharing staying painful faces a moral hazard of its own. And the underlying product already injures: skimpier plans have been found to deter people from seeking care and can burden the sick with considerable medical debt.

The false debate

Loans versus outrage is the wrong fight; medical credit already exists, and the live question is who designs it. The defenders deserve their strongest form: a lending option is, on this view, a workaround for the high cost of ACA plans, since a higher deductible buys a lower premium, and a regulated installment loan could genuinely beat a collections agency for a household with no cash buffer. The buffer really is missing: among single-person privately insured households, 32 percent did not have more than $2,000 saved. But the existing record of medical financing answers the optimism. Within two years of North Carolina's public university system going into business with AccessOne to finance patient payment plans, nearly half of its patients were in loans that charged interest. Americans paid an estimated $1 billion in deferred interest on medical debt in just three years, and the CFPB has warned against medical credit cards pitched right in doctors' offices. The outrage camp is right about the cruelty and wrong about the novelty. Credit at the hospital door is here; the choice is whether it gets rules.

Between the lines

The same government recommending the loans has been making the resulting debt more dangerous to carry. In July 2025 a federal court vacated the CFPB's rule keeping medical debt off credit reports, after the CFPB under the new administration joined the industry plaintiffs in asking for exactly that. The rule would have removed almost $50 billion from the credit reports of almost 15 million people. The court further concluded that federal law preempts state attempts to impose similar restrictions. Nor is the demand side an accident: CMS's own analysis projects that its marketplace rule could reduce enrollment by approximately 1.2 to 2 million individuals while increasing premiums by 2 to 3 percent. Read in sequence, the policy raises out-of-pocket exposure, strips the debt of protection, then invites insurers to finance the gap. That is not a market responding to need; it is policy-manufactured demand. It lands on a base of at least $220 billion in medical debt, roughly 107 million adults carrying some form of it, and half of adults with such debt saying cost stopped them from getting a test or treatment a doctor recommended.

Competing lenses

Two frameworks expose what the affordability language hides.

• The risk shift. Political scientist Jacob Hacker traced the decades-long migration of economic risk from institutions onto households: pensions became 401(k)s, salaries became gigs, comprehensive coverage became high deductibles. Insurer lending is the endpoint of that arc. The risk is not merely shifted onto the household; it is securitized there. Your exposure becomes their asset class.
• The noxious market. Philosopher Debra Satz argues that markets turn noxious when they spring from desperation, exploit weak agency, and produce severe harm. Borrowing from a hospital bed scores maximally on all three: no one comparison-shops credit mid-diagnosis. Satz's conclusion is not that every such market must be banned, but that it must be blocked or heavily structured. The industry's trade group says insurers are always evaluating innovative ways to promote affordability, which is precisely why the structure must arrive before the innovation does.

The playbook

If insurer credit is to exist, strip it of profit and wall it off from coverage. The agents are state insurance commissioners, acting through an NAIC model act, and CMS, through the conditions it attaches to qualified health plan certification.

• Zero-margin credit only. Permit insurer lending solely as 0 percent APR, fee-free deductible smoothing, booked as cost-sharing assistance rather than as an interest-bearing asset. If insurers decline to offer it on those terms, the product was a revenue line, not relief.
• A hard firewall. Repayment data may not inform underwriting, prior authorization, claims handling, or renewal. Nonpayment may never interrupt coverage or access to care. CMS can write this into certification for the federal exchange.
• The conversion rule. When a denied claim is later overturned on appeal, the loan that financed the gap converts to a covered benefit and is extinguished. This deletes the incentive to deny first and lend after.
• Income-scaled repayment, no reporting. Cap payments as a share of household income and bar insurer-issued medical loans from credit reports through plan certification terms, sidestepping the preemption fight now hanging over state reporting bans.
• The upstream truth. Congress restoring premium and cost-sharing support is the honest fix. States and CMS should not wait for it.

Final thought

Insurance was invented so that individuals would not have to borrow against catastrophe; the pool absorbs what no single household can. A pool that lends to its own members at interest has stopped pooling and started prospecting. First the risk moved from the institution to the household. Now the institution proposes to charge the household for carrying it.